论文部分内容阅读
目的:探讨检测CA_(125)、CA_(724)、CA_(199)及BFP对卵巢浆液性囊腺癌患者诊断及疗效监测的意义。方法:用RIA或EIA测定卵巢浆液性囊腺癌患者术前及术后24个月内血CA_(125)、CA_(724)、CA_(199)及BFP,以腹腔镜检查及剖腹探查术为对照,监测上述4项标记物。结果:(1)术前各项标记物的阳性率为57.1%～79.1%,以CA_(125)最高;3项标记物组合阳性率为79.1%～85.7%。(2)Ⅰ期患者组合阳性率达80%,而且3项组合测定(CA_(125)+CA_(724)+BFP)即可达此水平。(3)3例复发病例均有2项以上标记物超过界值,即3项标记物组合阳性率可达100%。(4)每项单独测定均有假阴性。(5)CA_(125)单独测定有1例假阳性。结论:标记物的组合测定可覆盖复发病例,也能有效地提示绝大部分早期病例,但应注意单独检测有假阴性和假阳性的问题。
Objective: To investigate the significance of detection of CA 125, CA 724, CA 199 and BFP in the diagnosis and treatment of ovarian serous cystadenocarcinoma. Methods: The levels of serum CA 125, CA 724, CA 199 and BFP in serous cystadenocarcinoma before and 24 months after operation were measured by RIA or EIA. Laparoscopy and laparotomy Control, monitoring the above four markers. Results: (1) The positive rates of various markers before operation ranged from 57.1% to 79.1%, with the highest value of CA 125. The positive rates of three markers were 79.1% -85.7%. (2) The positive rate of the combination of stage Ⅰ patients was 80%, and the combination of three (CA 125 (125) CA 724 BFP) reached this level. (3) There were more than two markers in 3 cases of recurrence exceeding the threshold value, that is, the positive rate of 3 markers combination reached 100%. (4) false negatives for each individual assay. (5) There was 1 false positive in CA 125 alone assay. CONCLUSIONS: The combination of markers can cover recurrent cases and can effectively prompt most early cases, but care should be taken to detect false negatives and false positives separately.